Related Experiment Videos
Therapeutic options for Huntington's disease.
Yvette A M Grimbergen1, Raymund A C Roos
1Department of Neurology K5Q 112, Leiden University Medical College, PO Box 9600, 2300 RC Leiden, The Netherlands.
Current Opinion in Investigational Drugs (London, England : 2000)
|March 11, 2003
Summary
Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a genetic defect. Current treatments manage symptoms, but new therapies aim to slow disease progression.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder.
- Characterized by CAG repeat expansion on chromosome 4, leading to striatal neuronal loss.
- Clinical manifestations include chorea, motor impairment, behavioral changes, and dementia.
Purpose of the Study:
- To review current symptomatic treatments for Huntington's disease.
- To focus on recent developments in new therapeutic approaches for HD.
- To discuss strategies for delaying disease progression.
Main Methods:
- Literature review of symptomatic treatments.
- Analysis of recent pharmacological developments.
- Discussion of emerging therapeutic strategies.
Main Results:
- Current therapies primarily manage HD symptoms.
- Pharmacological developments focus on disease-modifying treatments.
- New approaches aim to target underlying disease mechanisms.
Conclusions:
- Effective symptomatic treatments are available for Huntington's disease.
- Significant progress is being made in developing disease-modifying therapies.
- Future research holds promise for altering the course of Huntington's disease.